A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic Cholecystectomy

Inclusion Criteria: * 1.18 ≤ Age ≤ 70 years, no gender restriction. * 2.American Society of Anesthesiologists (ASA) physical status classification I-II. * 3.18 kg/m² ≤ BMI ≤ 30 kg/m². * 4.Subjects undergoing elective LC under general anesthesia, with an estimated -surgical duration of ≤2 hours (including 1h). * 5.Voluntarily agree to participate in the study and sign the informed consent form (ICF). Exclusion Criteria: * 1.History of allergy to nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, or intraoperative anesthetics specified in the protocol. * 2.Severe systemic diseases that, in the investigator's judgment, may significantly increase surgical risk or interfere with pain assessment (e.g., uncontrolled hypertension \[SBP ≥170 mmHg and/or DBP ≥105 mmHg\], uncontrolled hyperglycemia \[fasting blood glucose ≥11.1 mmol/L\], recent severe respiratory tract infection, severe gastritis, gastric/duodenal ulcers, upper abdominal surgery within 3 months, severe hepatic impairment \[Child-Pugh score \>9\], chronic kidney disease \[eGFR \<60 mL/min/1.73m²\]). * 3.Substance abuse: Current drug or alcohol dependency. * 4.Special populations: Pregnant or lactating women; any other conditions deemed unsuitable by the investigator. * 5.Acute severe cholecystitis attack within the past 7 days, or subjects in whom malignant gallbladder lesions cannot be ruled out. * 6.Presence of sleep disorders requiring pharmacological intervention; concomitant psychiatric disorders.